TABLE 4.

Clinical study of LAG-3 immune checkpoint drugs (lg fusion proteins and bispecifics).

Drug	Intervention	Clinic trial	Phase	Indication
IMP321	IMP321 + avelumab	—	—	Advanced solid tumors

Drug	Target	Clinic trial	Phase	Indication
MGD013 (Tebotelimab)	PD-1 + LAG-3	—	I	Relapsed or refractory DLBCL
FS118	PD-1 + LAG-3	NCT03440437	I/II	Advanced malignant neoplasm
RO7247669	PD-1 + LAG-3	NCT04524871	—	—
		NCT04785820
		NCT04140500
EMB-02	PD-1 + LAG-3	NCT04618393	I/II	Advanced solid tumors
XmAb841 (Pavunalimab)	CTLA-4 + LAG-3	NCT03849469	I	Advanced solid tumors
IBI323	PD-1 + LAG-3	—	I	Advanced malignant neoplasm
CB213	PD-1 + LAG-3	—	—	—